Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | CDC7 | O00311 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.31 |
| ▸ | PRKACA | P17612 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6668456 | 1.00 | USP8 (0.36) | USP8PTGS2MAPTKDM4EMEN1 | |
| SCHEMBL6790885 | 0.80 | SMN1; SMN2 (0.34) | MAPTKDM4EKMT2ASMN1; SMN2IDO1 | |
| SCHEMBL6790888 | 0.80 | SMN1; SMN2 (0.34) | MAPTKDM4EKMT2ASMN1; SMN2IDO1 | |
| SCHEMBL6480637 | 0.77 | SMN1; SMN2 (0.50) | MAPTKDM4EMEN1KMT2APOLB | |
| SCHEMBL6480632 | 0.77 | SMN1; SMN2 (0.50) | MAPTKDM4EMEN1KMT2APOLB | |
| SCHEMBL6791208 | 0.75 | HPGD (0.39) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6791207 | 0.75 | HPGD (0.39) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6492497 | 0.74 | USP8 (0.38) | USP8PTGS2MAPTKDM4EMEN1 | |
| SCHEMBL16144849 | 0.73 | USP8 (0.48) | USP8PTGS2MEN1KMT2ANPSR1 | |
| SCHEMBL6669676 | 0.70 | LRRK2 (0.38) | MAPTKDM4EMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| EP-1343499-A4 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | YU KUO-LONG (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1343499-A2 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002062290-A2 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067997-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | USP8 1933/4885PTGS2 1759/4885MAPT 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.